Chiome Bioscience Inc. (TYO:4583)

Japan · Delayed Price · Currency is JPY

86.00

+1.00 (1.18%)

Aug 27, 2026, 1:47 PM JST

Chiome Bioscience Financials Overview

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	615.15	593.29	780.81	682.46	630.82	712.93
Revenue Growth	-19.99%	-24.02%	14.41%	8.19%	-11.52%	48.26%
Gross Profit	375.24	355.58	432.85	398.6	348.86	422.46
Operating Income	-922.67	-979.77	-1,031	-1,205	-1,259	-1,334
Net Income	-925.73	-982.78	-1,021	-1,220	-1,243	-1,480
Earnings Per Share	-13.12	-14.47	-17.54	-24.62	-28.26	-36.74
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Drug Discovery Support Business	593.29	577.86	682.46
Drug Discovery Business	-	202.95	-
Total	593.29	780.81	682.46

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	1,372	1,205	2,063	1,326	1,727	1,791
Total Debt	67.5	86.7	281.5	291	184	183
Net Cash (Debt)	1,305	1,118	1,782	1,035	1,543	1,608
Net Cash Growth	7.42%	-37.23%	72.23%	-32.96%	-4.03%	-35.84%
Net Cash Per Share	18.49	16.47	30.61	20.88	35.09	39.92

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-801.81	-935.99	-1,001	-1,069	-1,191	-1,131
Capital Expenditures	-43.8	-40.08	-	-	-	-
Free Cash Flow	-845.61	-976.07	-1,001	-1,069	-1,191	-1,131
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	61.00%	59.93%	55.44%	58.40%	55.30%	59.26%
Operating Margin	-149.99%	-165.14%	-132.03%	-176.59%	-199.53%	-187.16%
Pretax Margin	-149.96%	-165.10%	-130.32%	-178.03%	-196.23%	-205.69%
Profit Margin	-150.49%	-165.65%	-130.73%	-178.77%	-197.03%	-207.58%
FCF Margin	-137.46%	-164.52%	-128.16%	-156.67%	-188.81%	-158.68%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 27, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	10.90	12.27	22.50	10.32	13.66	11.02